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tumor stage: a tissue microarray study in head 
and neck cancer patients
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Abstract 
Background: Human papillomaviruses (HPVs) and Epstein–Barr virus (EBV), known oncoviruses, can be co‑present 
and cooperate in the initiation and/or progression of human carcinomas, including head and neck. Based on this fact, 
we recently reported the prevalence of both HPVs and EBV in cervical and breast cancers.
Methods: We herein explore for the first time the co‑prevalence of high‑risk HPVs and EBV in 98 head and neck (HN) 
squamous cell carcinoma (SCC) tissues from Bosnian patients using polymerase chain reaction (PCR) and immunohis‑
tochemistry (IHC) analysis, as well as tissue microarray methodology.
Results: The majority of these cancer tissue cases were from the oral cavity (68%). We found that high‑risk HPVs and 
EBV are co‑present in 34.7% of the SCC samples; with a significant correlation between the various HPV types and EBV 
co‑incidence (p = 0.03). Our data showed that 30.8% of oral SCCs are positive for E6 oncoprotein of high‑risk HPVs and 
44.6% are positive for LMP1 of EBV. The most commonly expressed HPVs in our HNSCC samples include HPV types 16, 
18, 45 and 58. Additionally, 37.5% of oral SCCs are positive for both HPVs and EBV, with statistically significant associa‑
tion between high‑risk HPV types and EBV (p < 0.05). More importantly, our data revealed that the co‑presence of HPV 
and EBV is strongly correlated with advanced tumor stage (p = 0.035).
Conclusion: In this study we show that HPV and EBV oncoviruses are co‑present in HNSCC, particularly in oral cancer, 
where they can cooperate in the initiation and/or progression of this cancer. Thus, further studies are necessary to 
elucidate the mechanism of this cooperation.
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Introduction
Head and neck (HN) cancers are a group of malignant 
neoplasms arising from the oral cavity, craniofacial 
bones, nose, larynx, pharynx as well as the salivary glands 
[1]. These cancers are the tenth most frequently occur-
ring cancer worldwide [2] comprising of 5–50% of all 
cancers [3]. The majority of the HN cancers originate 
from the epithelium lining of the oral cavity, pharynx and 
larynx, indicating squamous differentiation [1]. Histo-
logically, squamous cell carcinoma (SCC) constitute most 
tumors found in the head and neck region (~ 90%) [1, 4] 
followed by other histological types such as lymphomas, 
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sarcomas or blastomas [4]. The main features of this dis-
ease include late diagnosis, high mortality rates and mor-
bidity [5, 6].
Tobacco consumption is the primary known cause of 
HN cancers including oral [5] followed by viral infec-
tions by high-risk human papillomaviruses (HPVs) and 
Epstein-Barr virus (EBV) that are associated with the 
development and/or progression of head and neck (HN) 
carcinomas [7–9].
Human papillomaviruses (HPVs) are human oncovi-
ruses that are sexually transmitted and are strongly asso-
ciated with cervical carcinomas [10]. HPVs are small, 
double-stranded DNA viruses which tend to infect cuta-
neous and mucosal epithelial tissues of the ano-genital 
tract [11]. HPVs are categorized into high-risk or low-
risk, with high-risk types duly linked with the onset and 
progression of cancer [10, 12]. While, low-risk HPV sub-
types induce multiplication of epithelial cells that develop 
into warts or skin papillomas [13, 14]. Earlier investiga-
tions indicated that persistent infection with high-risk 
HPVs is critical for the development of invasive carci-
nomas [10, 15]. Moreover, it was pointed out that their 
presence is linked with tumor size, vascular invasion and 
lymph node metastases [16–20]; which makes them a 
useful prognostic factor in early-stage cervical, HN, and 
colorectal carcinomas. In addition, it has been pointed 
out that E6/E7 oncoproteins of high-risk HPVs convert 
non-invasive and non-metastatic cancer cells into inva-
sive and metastatic form [21].
On the other hand, Epstein–Barr virus (EBV), a human 
DNA oncogenic gamma-1 herpesvirus affects around 
90% of adults [22]. During EBV infection, cells express 
six EBV nuclear proteins (EBNA1, -2, -3A, -3B, -3C, 
and -LP), three latent membrane proteins (LMP1, -2A, 
and -2B), and multiple non-coding RNAs (EBERs and 
miRNAs) [23–25]. EBV virus is associated with a broad 
spectrum of diseases including multiple sclerosis (MS), 
infectious mononucleosis (glandular fever) and it has the 
potential to transform B lymphocytes which causes vari-
ous malignancies, including lymphoid. Additionally, EBV 
infection is linked with several types of epithelial carci-
nomas [26]. While, all cases of undifferentiated naso-
pharyngeal carcinoma are EBV-associated [27], in gastric 
cancer EBV is present only in a subset of gastric cancers 
[28, 29]. However, in breast and cervical cancers, the role 
of EBV is controversial; while a few studies have detected 
EBV presence in these cancers [30–34], other studies 
failed to detect it [35–39].
EBV’s key oncogenic protein LMP1 induces cell 
growth, decreases apoptosis, promotes cell motility and 
angiogenesis and is also known to express frequently in 
human oral cancer [40, 41]. Moreover, various EBV genes 
including latent genes contribute to transformation of 
human B and some oral epithelial cells and are continu-
ally expressed in EBV-associated cancer cells, which links 
EBV with viral oncogenesis [42–44]; for example, expres-
sion of EBNA1, LMP1, -2A genes characterize type II 
latency and is linked with Hodgkin’s lymphoma and some 
carcinomas like gastric, nasopharyngeal and breast [22, 
26].
Accumulating evidence show that infection with at 
least one type of high-risk HPV alone is not sufficient 
to induce neoplastic transformation; high-risk HPV-
infected cells must undergo further genetic changes and/
or co-infection with another oncovirus to attain com-
plete cellular transformation and consequently tumor 
development [31, 32, 42, 45–48]. Hence, in this study, 
we explored the co-presence of high-risk HPVs and EBV 
in HN cancer samples from Bosnian patients. Our study 
pointed out that EBV and HPVs are co-present in 34.7% 
of our samples, and their co-presence is associated with 
advanced tumor stage.
Materials and methods
Sample collection and ethical approval
All samples were taken from formalin-fixed paraffin-
embedded (FFPE) tissues from surgically removed 
and pathologically confirmed squamous cell carcino-
mas of the head and neck. The samples were retrieved, 
and approved to be used for research, from the pathol-
ogy archive of the Department of Pathology, Clinical 
Center, University of Sarajevo. All samples for the study 
were de-identified, therefore the patient consent was not 
needed per local protocol. Only cases having at least one 
redundant FFPE block were used in the study. The Qatar 
University Institutional Biosafety Committee (IBC) and 
Institutional Review Board (IRB) committees approved 
the project (Numbers: QU-IBC-2018/064 and APP-
16/05/2018/GCC). The study was performed in accord-
ance with relevant guidelines and regulations of these 
committees at Qatar University.
Prior to molecular assays, all hematoxylin and eosin 
(H&E) slides were re-reviewed by board-certified pathol-
ogists (Drs. Semir Vranic and Faruk Skenderi) to confirm 
the diagnosis and select appropriate samples for tissue 
microarray and molecular assays (PCR and IHC).
DNA extraction
DNA extraction from FFPE tissues was performed using 
Qiagen AllPrep DNA/RNA FFPE Kit (Qiagen, Ltd., 
Crawley, UK). Briefly, aliquots of 200 μl of samples were 
digested with 20  μl of K proteinase and 200  μl of AL 
buffer at 56  °C, for 10 min. DNA precipitation was per-
formed by adding 200 μl of 96% ethanol. DNA was eluted 
in 200 μl of AE buffer and stored at − 20 °C until further 
Page 3 of 13Al‑Thawadi et al. Cancer Cell Int          (2020) 20:361  
use. The samples collection and DNA extraction were 
achieved as previously illustrated [49, 50].
HPV and EBV detection
Twenty-five nanograms of purified genomic DNA from 
each sample was analyzed for EBV and HPV by polymer-
ase chain reaction (PCR) as previously described [51] 
using specific primers for LMP1 as well as E6/E7 of HPV 
types: 16, 18, 31, 33, 35, 45, 51, 52 and 58. MY09/MY11 
and GP5 +/GP6 + primers were also used to amplify the 
L1 region of the viral genome which is commonly used 
for HPV detection in clinical and histological studies 
[52]. GAPDH primers (Forward Primer: 5′-GAA GGC 
-CAT GCC AGT GAG CT-3′ and Reverse Primer: 5′-CCG 
GGA AAC TGT GGC GTG AT-3′) were used as an internal 
control. Primers and analysis was performed as previ-
ously described by our group [49, 50].
Briefly, LMP1 gene (Forward Primer: 5′-TTG GAG ATT 
CTC TGG CGA CT-3′ and Reverse Primer: 5′-AGT CAT 
CGT GGT GGT GTT CA-3′) was amplified for an initial 
denaturation at 95 °C for 10 min followed by 40 cycles of 
95  °C for 30 s, 61  °C for 1 min, and 72  °C for 1 min. In 
parallel, HPV gene was amplified for an initial denatura-
tion at 95 °C for 10 min followed by 40 cycles of 95 °C for 
30 s, annealing at temperatures ranging from 50 to 62 °C 
for 1 min depending on each primer’s melting tempera-
ture as previously described [49], and 72  °C for 1  min. 
Samples were finally incubated for 10 min at 72  °C for a 
final extension. The PCR product from each exon was 
resolved by using 1.5% agarose gel electrophoresis.
In each experiment, a negative control (sterile water 
instead of DNA) and a positive control (such as Hela and 
Siha cell lines) were used.
Tissue microarray (TMA)
Tissue microarray construction was attained as described 
previously by our group [31, 32, 53]. Briefly, cancer sam-
ples and controls were embedded into a virgin paraf-
fin TMA block using a manual tissue arrayer (Beecher 
Instruments, Silver Spring, MD, USA). All FFPE samples 
were de-identified and assembled without any previ-
ous knowledge of linked clinical or pathological staging 
information.
Two TMA cores of 1.0 mm in diameter were sampled 
from a cohort of 98 FFPE samples from Bosnian patients 
with confirmed oral squamous cell carcinoma. Later, sec-
tions of 4 µm were cut and stained with hematoxylin and 
eosin on the initial slides to verify the histopathologic 
diagnosis (cancer tissues). Next, slides of the completed 
blocks were used for immunohistochemistry (IHC) 
assays (against E6 and LMP1 of high-risk HPV and EBV, 
respectively).
Immunohistochemistry (IHC)
Immunohistochemical analysis investigating the expres-
sion of E6 of HPV and LMP1 of EBV were performed 
using procedures as previously described [53]. To ana-
lyze protein expression patterns of E6 and LMP1 in 
TMA slides, each slide was deparaffinized in graded 
alcohol, rehydrated and boiled (microwave) in 10  mM 
citrate sodium citrate solution (pH 6.0) for 10 min. 
Endogenous peroxidase activity within the rehydrated 
tissue was blocked with a solution of 3% hydrogen per-
oxide in methanol for 10 min at room temperature. TMA 
slides were further incubated for 35 min at 37  °C with 
primary monoclonal antibodies for E6 of HPV (clones 
1–4 and C1P5, Dako Agilent, Carpinteria, CA and Cal-
biochem, Canada) and LMP1 of EBV using a fully auto-
mated immunostainer (Ventana Medical System, Tuscon, 
AZ). The fully automated Ventana Medical System uses 
an indirect biotin–avidin system with a universal bioti-
nylated immunoglobulin secondary antibody. The slides 
were counterstained with hematoxylin prior to mounting. 
The staining procedures were completed according to 
the manufacturer’s recommendations. Negative controls 
were obtained by omitting specific primary antibody for 
E6 and LMP1 as well as specific blocking peptides from 
Santa Cruz Biotechnology.
The tumors were considered positive for E6 and LMP1 
if cancer cells exhibited positivity ≥ 1% of the cells [32]. 
In case of LMP1 protein expression (EBV), we also evalu-
ated the presence of viral infection in tumor-infiltrating 
lymphocytes and stromal cells [32].
Statistical analysis
Statistical analysis was performed using IBM Statistical 
Package for the Social Sciences (version 25) and R. Data 
were calculated as non-parametric files. Spearman Cor-
relation Rank test was used to assess the significance of 
HPV and EBV association. We utilized χ2 test with Yates 
correction to assess the significance of the association 
between clinicopathological data (patient’s age, cancer 
grade and tumor stage) and the co-presence of HPVs and 
EBV. Statistical significance was achieved at p < 0.05.
Results
Clinicopathological characteristics of the cohort
The cohort of head and neck carcinomas included 123 
cases and 17 squamous cell carcinomas from other ana-
tomic locations (skin, cervix and esophagus) making a 
total of 140 cases. After careful assessment, ninety-eight 
cases had available FFPE blocks for TMA and PCR.
The mean age of patients was 62.8  years (range, 
24–91  years), the majority of them were male (72.8%) 
(Table  1). All cancers in the study are histologically 
Page 4 of 13Al‑Thawadi et al. Cancer Cell Int          (2020) 20:361 
squamous cell carcinomas (SCC). The study included 
cancers originating from the oral cavity (66.4%) followed 
by cancer of the larynx (17.9%). Cancers of the pharynx 
and other anatomic locations (skin, cervix) were rare and 
comprised only of 3.6% and 10.7% of the cases, respec-
tively (Table 1).
Of the studied cases, there are twenty-four well-differ-
entiated carcinomas cases (17.1%) (G1), 85 moderately 
differentiated (60.7%) (G2) and 16 poorly differenti-
ated (11.4%) (G3) (Table 1; Figs. 1a, b, 2a, b, 3a, b, 4a, b). 
Based on the tumor stage, 41 (29.3%) cases are stage 1, 
39 (27.9%) cases are stage 2, while, 21 (15%) cases are 
reported to have stage 3 and 30 (21.4%) cases are stage 4 
(Table 1).
Presence of high‑risk HPV subtypes and EBV by PCR
Ninety-eight SCC samples had interpretable results for 
HPV and EBV by PCR (Additional files 1, 2: Figures  S1 
and S2).
It revealed that 55 (56.1%) of the samples are positive 
for E6 of high-risk HPVs and 68 (69.3%) of the samples 
are positive for LMP1 of EBV. Out of ninety-eight SCC 
samples, 34 (34.7%) are positive for both HPVs and EBV 
(Table  2). In addition, there is a significant correlation 
between the coincidence of EBV with various HPV types 
[HPV 16 (p = 0.03), HPV18 (p = 0.003), HPV45 (p = 0.04), 
HPV58 (p = 0.02)] in HNSCC samples (Table 2).
Our data showed that, the most commonly expressed 
high-risk HPVs in Bosnian HNSCC samples are HPV18 
Table 1 Clinicopathological characteristics of  the  cohort of  the  patients with  squamous cell carcinoma (oral cavity 
and other locations)
Characteristic Categories Number (%)
Gender Male 102 (72.8)
Female 38 (27.1)
Squamous cell carcinoma histology (by anatomic location) Oral cavity 93 (66.4)
Larynx 25 (17.9)
Pharynx 5 (3.6)
Other locations (skin, cervix) 15 (10.7)
Unknown 2 (1.4)
Cancer grade G1 24 (17.1)
G2 85 (60.7)
G3 16 (11.4)
Unknown 15 (10.7)
Tumor (pT) stage pT1 41 (29.3)
pT2 39 (27.9)
pT3 21 (15.0)
pT4 30 (21.4)
Unknown 9 (6.4)
HPV (E6) oncoprotein expression (IHC) Oral cavity 21 (44.6)
Larynx 14 (87.5)
Pharynx 4 (80)
Other locations (skin, cervix) 1 (16.6)
EBV (LMP1) oncoprotein expression (IHC) Oral cavity 35 (76)
Larynx 1 (33.3)
Pharynx 3 (100)
Other locations (skin, cervix) 2 (40)
HPV (E6) oncoprotein expression (PCR) Oral cavity 29 (45.3)
Larynx 17 (70.8)
Pharynx 3 (60)
Other locations (skin, cervix) 3 (60)
EBV (LMP1) oncoprotein expression (PCR) Oral cavity 50 (78.1)
Larynx 14 (21.8)
Pharynx 1 (4.1)
Other locations (skin, cervix) 3 (60)
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(56%) followed by HPV58 (48%), HPV45 (27%), HPV16 
(21%), HPV52 (14%), HPV31 and HPV51 (9.2% each) and 
HPV 35 (3%) (Fig. 5). Moreover, 13 (13.2%) of the 98 sam-
ples are co-infected with both HPV16 and 18 (Fig. 6).
Moreover, the Bosnian HNSCC cancers were co-
infected with more than one type of HPV in 49 out of 
98 samples (50%). Figure  6 shows the most common 
Fig. 1 a–d The case of moderately differentiated (G2) oral squamous cell carcinoma (a, b Hematoxylin and Eosin staining) with a diffuse and strong 
expression of E6 protein of HPV by immunohistochemistry (a and c figures, ×4 magnifications; b and d figures, ×20 magnifications)
Fig. 2 a, b The case of moderately differentiated (G2) squamous cell carcinoma with negative IHC reaction against E6 of HPV (image A at ×10 
magnification and image B at ×20 magnification)
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co-infections of HNSCC samples with HPV18 and 
other high-risk HPV subtypes.
Regarding the anatomical distribution of these oncovi-
ruses, out of the 98 cases, anatomical location was avail-
able for 94 cases. Thus, twenty-nine of the sixty-four oral 
SCC samples (45.3%) were positive for E6 of high-risk 
HPVs and 50 (78.1%) of them were positive for LMP1 
of EBV. On the other hand, 37.5% of oral SCC samples 
were positive for both HPVs and EBV. In addition, in oral 
cancer samples, a significant association was observed 
Fig. 3 a–d The case of poorly differentiated (G3) oral squamous cell carcinoma (a, b Hematoxylin and Eosin staining) that was diffusely and strongly 
positive for LMP1 protein of EBV (c, d); This cancer also strongly co‑expressed E6 protein of HPV (the image in the right upper corner of b) (a–c ×4 
magnifications; b–d ×20 magnifications)
Fig. 4 a, b The case of poorly differentiated (G3) squamous cell carcinoma with negative IHC reaction against LMP1 of EBV (image a at ×10 
magnification and image b at ×20 magnification). The red arrows in image B indicate the positive reaction of LMP1 in tumor‑infiltrating 
lymphocytes
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between EBV and several high-risk HPV types [HPV-16 
(p = 0.000), HPV-18 (p = 0.0005), HPV-31 (p = 0.000), 
HPV-35 (p = 0), HPV-45 (p = 0.006), HPV-51 (p = 0.000), 
HPV-58 (p = 0.02)].
Expression patterns of E6 and LMP1 of high‑risk HPVs 
and EBV
Seventy-nine samples were used for IHC to detect 
high-risk HPV E6. The remaining 19 cases were not 
interpretable due to sparsity of cancer tissue in the 
TMA cores. The frequency of E6 of HPV positivity 
in these samples by IHC was 57% (45/79), which is in 
agreement with the PCR data, where 56.1% (55/98) of 
SCC samples were positive for E6 of HPV (Table  2). 
Thirteen cases (16.5%) exhibited diffused (90–100%) 
and strong HPV E6 protein expression in cancer cells 
(Fig.  1c, d) while ten cases (12.6%) had low HPV E6 
expression (1–25% positive cancer cells). The positivity 
of E6 oncoprotein of high-risk HPV was predominantly 
observed in cancer cells (Fig.  1c, d). It was both cyto-
plasmic and nuclear. Rarely, high-risk HPV E6 oncopro-
tein expression was noted in cancer stroma (fibroblasts 
and inflammatory cells) (Fig.  1c, d). The remaining 34 
cases were negative for E6 of HPV (Fig. 2).
Table 2 Prevalence of high-risk HPV types in relation to EBV status in HNSCC cohort (n = 98)
Significant p‑values are denoted by asterisk (*)
Samples No. of cases High‑risk HPV types
16 18 31 33 35 45 51 52 58
EBV (+) 68 10 31 8 0 0 20 7 10 27
EBV (−) 30 11 24 1 0 3 7 2 4 20
Total 98 21 55 9 0 3 27 9 14 47
p‑value 0.03* 0.003** 0.34 N/A N/A 0.04* 0.85 0.89 0.02*
Fig. 5 The distribution of each high‑risk HPV subtype by PCR according to the frequency in the HNSCC cohort (n = 98)
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Additionally, using IHC we found that the expression 
of E6 of high-risk HPV was detected highly in the larynx 
(87.5%) and pharynx (80%) followed by the oral cavity 
(44.6%) (Table  1); Results are comparable to PCR data, 
where HPV was highly expressed in the larynx (70.8%) 
and pharynx (60%) followed by the oral cavity (45.3%) 
(Table 1).
LMP1 oncoprotein of EBV was available for 68 cases, as 
nine cases were not assessable due to sparse or complete 
absence of cancer tissue. LMP1 was positive in 42 (71%) 
of the 59 cases which also correlated with EBV PCR data 
(positivity 69.3%). The mean percentage of LMP1 pro-
tein in cancer cells was 46% (range, 0–95%) (Fig. 3c, d). 
LMP1 was predominantly cytoplasmic and membranous 
(Fig.  3c, d). No nuclear expression was observed in any 
of the tested cases. LMP1 protein was occasionally posi-
tive in cancer stroma (lymphocytes) (Fig.  4a, b) as well 
as in immune cells (lymphocytes) of the TMA cores that 
contained no cancer tissues but normal tissue with some 
inflammatory cells (data not shown).
LMP1 was also highly expressed in the pharynx (100%) 
followed by oral cavity (76%) and larynx (33.3%) (Table 1).
Seventeen of the 57 samples (29.8%) were positive 
(≥ 1% positive cancer cells) for both EBV and HPVs in 
SCC (Fig.  3b); nevertheless, in our PCR data, co-inci-
dence in SCC samples was 34.7%. Seven cases were both 
HPV and EBV negative. In addition, we found statistically 
significant association between various HPV types and 
EBV co-infection (p = 0.03) in SCC; this data is in con-
cordance with our PCR data.
Correlation of clinicopathological characteristics with HPV/
EBV positivity
HPV positivity correlated strongly with tumor grade 
(p = 0.02), tumor stage (pT) (p < 0.001) and advanced 
pN stage (p = 0.045) (Table  3). On the other hand, EBV 
positivity had no significant association with tumor grade 
(p = 0.47), tumor stage (p = 0.53) and pN stage (p = 0.14) 
(Table 3).
More significantly, we found that the co-expression of 
LMP1 of EBV and E6 of high-risk HPVs (EBV +/HPV +) 
is associated with advanced tumor stage (p = 0.035) 
(Table 4); nevertheless, no positive association was found 
with tumor grade (p = 0.4) (Fig. 3b).
Fig. 6 The distribution of co‑infection of HPV18 with other high‑risk HPV subtypes in HNSCC. The most commonly co‑infected subtype was 
HPV18/58 (33/98; 33.7%) followed by HPV18/45 (17/98; 17.3%), HPV18/16 (13/98; 13.2%), HPV 18/52 (12/98; 12.2%), HPV18/31 (7/98; 7.1%), HPV18/35 
and HPV16/51 (3/98; 3.1% each). Since, HPV33 was not present in the cohort, there was no co‑expression for HPV18 with these subtypes
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Discussion
Oncovirus infections are one of the main underlying 
sources for the onset and progression of infection-related 
cancer cases [54, 55]. Viral infections are primarily domi-
nant in developing countries; however, their occurrence 
cannot be overlooked in developed countries [56, 57].
High-risk HPVs and EBV are important etiological 
factors in human HN cancer, especially oral; as approxi-
mately 35% and 55% of oral cancers are positive for these 
viruses, respectively [48]. Moreover, several studies have 
indicated the co-presence of high-risk HPVs and EBV in 
human oral cancer [42, 48, 58–60] and hence this study 
aims to investigate the co-presence of high-risk HPVs 
and EBV in tissue specimens of HN cancer from Bosnia 
in relation to tumor phenotype. Both EBV and high-risk 
HPVs share various features in terms of infection of oral 
epithelial tissue; these viruses infect and lead to epithelial 
tissue differentiation from the upper aero-digestive tract 
which stimulates both prolific and lytic phases of HPV’s 
and EBV’s life cycle, respectively [61].
Approximately 38% of virus-related cancers, display 
presence of EBV in addition to high-risk HPVs [55]; 
especially types 16, 18, and 33, which cumulatively infect 
80–90% of the population worldwide [48]. Combined 
oncogenic effects of viral infections can lead to the onset 
and progression of cancer [48, 55].
In this study, EBV infection was observed in 69.3% of 
SCC cases by PCR analysis, of which 78.1% was found in 
the oral cavity, this is in concordance with other inves-
tigations in oral carcinomas where EBV infection was 
found to be higher than 50% [58–60]. Jaloluli et  al. [62, 
63] examined the presence of EBV in eight different 
countries and showed an average of 55% EBV preva-
lence (22% in Yemen to 80% in the UK), suggesting EBV 
infection in oral cancer to be dependent on geographical 
region [64, 65].
On the other hand, we found that 45.3% of oral cancer 
cases are positive for high-risk HPVs, similar to previous 
studies [60]. The most frequent high-risk HPV types in 
Bosnian SCC patients are (HPVs-16, -18, -45 and -58) 
(21.4%, 56.1%, 27.5% and 47.9%, respectively. It is impor-
tant to highlight that, Iljazović et  al. [66] reported that 
the most frequent HPVs in cervical cancer in Bosnian 
women are types 16, 18, 45, 33, 51 and 31, respectively. 
However, there are no studies to date regarding the pres-
ence of HPVs in HN cancer, including oral, in Bosnia.
Regarding the co-incidence of HPV and EBV in oral 
carcinoma, our study showed a higher rate of infection 
(37.5%) in comparison with other HN carcinomas (lar-
ynx and pharynx) including the skin and cervix (< 5%). 
Furthermore, HPV-18 accounted for the majority of oral 
carcinomas (45.3%) compared with other HN carcinomas 
(larynx and pharynx) including the skin and cervix carci-
nomas (< 3%), which have been previously reported [67]. 
While, a study by Fregonesi et al. found HPV 16/18 posi-
tivity in 40% of Brazilian oral premalignant lesions [68]; 
Shroyer et al. found 17% of HPV16/18 positivity in sam-
ples from Colorado of the USA [69]. Our study showed 
that 12.5% of our samples are positive for HPV16/18, 
which is in accordance with a study by Agrawal et  al. 
where they found 10% HPV16/18 positivity in oral epi-
thelial dysplasia in India [70].
As reported earlier, high-risk HPV inhibits changes 
in the EBV genome in normal oral cells and induces 
EBV lytic recurrence in differentiating epithelial cells, 
indicating co-infection with HPV might enhance EBV-
directed pathogenesis in the oral cavity [61]. Several 
studies showed co-infection by high-risk HPVs and EBV 
in roughly 38% of human nasopharyngeal carcinomas 
[58, 71, 72]; our study showed comparable results where 
Table 3 Correlation of  clinicopathological characteristics 
with HPV presence
*Significant p‑values
Degree of differentiation HPV (E6) 
positive (%)
HPV (E6) 
negative (%)
p‑value
Tumor grade
 Well‑differentiated 6 (8.6) 9 (13) p = 0.02*
 Moderately‑differentiated 23 (33.3) 20 (28.9)
 Poorly‑differentiated 10 (14.4) 1 (1.4)
 Total 39 (56.5) 30 (43.4)
Tumor Stage (pT)
 pT1 3 (4.4) 14 (20.8) p < 0.001*
 pT2 10 (14.9) 12 (17.9)
 pT3 13 (19.4) 2 (2.9)
 pT4 10 (14.9) 3 (4.4)
 Total 36 (53.7) 31 (46.2)
pN Stage
 pN0 11 (29.7) 8 (21.6) p = 0.045*
 pN1 8 (21.6) 2 (5.4)
 pN2 7 (18.9) 1 (2.7)
 Total 26 (70.2) 11 (29.7)
Table 4 Correlation of  clinicopathological characteristics 
with EBV/HPV positivity
*Significant p‑values
Stages HPV ±/EBV ± (%) HPV +/EBV + (%) p‑value
pT1 16 (29) 2 (3.6) p = 0.035*
pT2 14 (25.4) 5 (9)
pT3 4 (7.2) 5 (9)
pT4 4 (7.2) 5 (9)
Total 38 (69) 17 (30.9)
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oral cancer cases were co-infected by high-risk HPVs and 
EBV in 37.5% of the cases. Moreover, we herein found 
significant association between the co-presence of EBV 
and high-risk HPVs in SCC. These results are in agree-
ment with a study performed by Jiang et  al. [73] where 
significant correlation was found between EBV and HPV 
in oropharyngeal cancers [73]. Although, several inves-
tigations have been conducted, nevertheless, the exact 
role of EBV and HPV interaction in human carcinogen-
esis has not clearly been identified [74]. While, Makielski 
et al. [61] suggested that HPV infection in the oral cav-
ity may enhance the capacity of epithelial cells to support 
EBV life cycle, which can further enhance EBV-mediated 
pathogenesis in the oral cavity. On the other hand, a study 
by Guidry and Scott [75] denoted that co-infection by 
HPV and EBV might escalate EBV persistence either via 
latency or increased viral replication and by increasing 
HPV oncogene expression. In this regard, it is well estab-
lished that high-risk HPV infection alone is not enough 
to stimulate neoplastic transformation of normal human 
epithelial cells [45]; thus, HPV could interact with other 
oncoviruses such as EBV to induce cell transform of dif-
ferent types of human epithelial cells including oral [42, 
76], indicating the importance of further genetic changes 
or co-infection with other oncoviruses. Previous research 
by our group showed that E6/E7 of HPV type 16 along 
with ErbB-2, which is upregulated in 30% of oral carcino-
mas  [77], induce cellular transformation of oral epithelial 
cells [46] via β-catenin tyrosine phosphorylation by pp60 
(c-Src) kinase activation [46, 78]. On the other hand, EBV 
can infect and immortalize human primary epithelial 
cells in vitro [45, 79]. Among several known EBV genes, 
it was reported that LMP1 and BARF1 can induce malig-
nant transformation in rodent fibroblasts   [80, 81], indi-
cating their role as viral oncogenes.
Mellin et  al. [82] found a significant association 
between TNM staging and HPV positivity. Our results 
are in accordance with this study, by showing that high-
risk HPV presence is correlated with poorly differen-
tiated SCC (p = 0.02), tumor stage (p < 0.001) as well 
as more advanced pN stage (p = 0.045). Moreover, we 
herein demonstrate for the first time that the co-presence 
of EBV and high-risk HPVs is associated with advanced 
tumor stage (p = 0.035); suggesting that high-risk HPVs 
and EBV oncoproteins can cooperate in the initiation 
and/or progression of human oral cancer.  Therefore, 
coinfections with high-risk HPV subtypes and EBV can 
enhance the onset and progression of oral or oropharyn-
geal tumors [58]. Thus, blocking of EBV lytic replication 
due to induction of HPV may lead to EBV latency which 
has been linked with invasive phenotype and deferred 
differentiation in oral keratinocytes latently infected with 
EBV [83, 84]. Therefore, HPV-induced EBV latency can 
be associated with long-term EBV oncogene expression 
that could contribute in the progression of HPV + oral 
SCC [85]. In this context, our group, previously pointed 
out the possible cooperative role of LMP1 and/or EBNA1 
genes of EBV as well as E5 and E6/E7 genes of high-risk 
HPVs in the initiation and/or progression of different 
types of human carcinomas via the EMT event [47].  In 
the present study, EBV +/HPV + showed positive cor-
relation with advanced tumor stage (p = 0.035), how-
ever, no positive association was found with tumor grade 
(p = 0.4); thus, lack of association between the co-pres-
ence of these oncoviruses and tumor grade can be due to 
the relatively small sample size.
Conclusions
In this study, we explored, for the first time, the co-pres-
ence of EBV and high-risk HPVs in human HN cancer 
from Bosnia. Our data revealed that the most frequent 
high-risk HPVs in HN cancers in the Bosnian population 
are HPV types 18, 58, 45 and 16, respectively. Moreover, 
we report that EBV and high-risk HPVs are co-present in 
34.7% of our HN cancer samples. More significantly, our 
investigation pointed out that the co-presence of EBV 
and high-risk HPVs is strongly associated with advanced 
tumor stage of HN cancer, which suggests that these 
oncoviruses can cooperate in the progression of this 
cancer. Thus, we believe that more investigations with a 
larger number of samples are necessary to confirm these 
findings which could be very important in the prevention 
of HN cancer as well as other EBV and HPVs associated 
cancers via selecting the right vaccine for specific popula-
tions. Meanwhile, mechanistic studies are crucial to elu-
cidate the cooperation role of EBV and high-risk HPVs in 
the initiation and/or progression of human HN cancer.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 5‑020‑01348 ‑y.
Additional file 1: Figure S1. Representative PCR reactions for HPV‑sub‑
types in 15 different HNSCC patients.
Additional file 2: Figure S2. Representative PCR reactions for EBV (LMP1) 
in 15 different HNSCC patients.
Abbreviations
DNA: Deoxyribonucleic acid; EBV: Epstein–Barr virus; EBNA: EBV‑encoded 
nuclear antigens; HPV: Human papilloma virus; HNSCC: Head and neck squa‑
mous cell carcinoma; IHC: Immunohistochemistry; LMP: Latent membrane 
protein; PCR: Polymerase chain reaction; TMA: Tissue microarray.
Acknowledgements
The authors would like to thank Mrs. A. Kassab for her critical reading of the 
manuscript. The publication of this article was funded by the Qatar National 
Library.
Page 11 of 13Al‑Thawadi et al. Cancer Cell Int          (2020) 20:361  
Authors’ contributions
Conceptualization, AEA, SV and HA; Methodology, AJ, IG, AY, TA and SV; valida‑
tion, AJ, IG, and SV; Formal analysis, AJ, IG, FS, HA and SV; Writing—original 
draft preparation, IG; Writing—review and editing, IG, SV, MIM, HA and AEA; 
Supervision, HA, AEA, GB and SV. Funding acquisition, HA and AEA. All authors 
read and approved the final manuscript.
Funding
This work was supported by grants from Qatar University: GCC‑2017‑
002 QU/KU, QUCG‑CMED‑2018\2019‑3, QUCG‑CMED‑20/21‑2 and 
QUHI‑CMED‑19/20‑1.
Availability of data and materials
All data generated or analyzed during this study are included in this published 
article (and its addiitonal files).
Ethics approval and consent to participate
This study was approved by Qatar University IBC and IRB committees (Num‑
bers: QU‑IBC‑2018/064 and APP‑16/05/2018/GCC). On the other hand, use of 
anonymous samples was approved by the Department of Pathology, Clinical 
Center, University of Sarajevo.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1 College of Medicine, QU Health, Qatar University, P. O. Box 2713, Doha, Qatar. 
2 Department of Pathology, Clinical Center, University of Sarajevo, 71000 Sara‑
jevo, Bosnia and Herzegovina. 3 Segal Cancer Center/Lady Davis Institute 
for Medical Research, JGH/McGill University, Montreal, QC, Canada. 4 Biomedi‑
cal Research Centre, Qatar University, P. O. Box 2713, Doha, Qatar. 
Received: 11 November 2019   Accepted: 15 June 2020
References
 1. Pai SI, Westra WH. Molecular pathology of head and neck cancer: 
implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 
2009;4:49–70.
 2. Fan C‑Y. Epigenetic alterations in head and neck cancer: prevalence, clini‑
cal significance, and implications. Curr Oncol Rep. 2004;6(2):152–61.
 3. Garfinkel L. Perspectives on cancer prevention. CA Cancer J Clin. 
1995;45(1):5–7.
 4. Adeyemi BF, Adekunle LV, Kolude BM, Akang EEU, Lawoyin JO. Head and 
neck cancer—a clinicopathological study in a tertiary care center. J Natl 
Med Assoc. 2008;100(6):690–7.
 5. Gupta N, Gupta R, Acharya AK, Patthi B, Goud V, Reddy S, et al. Chang‑
ing trends in oral cancer—a global scenario. Nepal J Epidemiol. 
2016;6(4):613–9.
 6. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal 
cancer. Oral Oncol. 2009;45(4):309–16.
 7. Venuti ABG, Rizzo C, Mafera B, Rahimi S, Vigili M. Presence of HPV in head 
and neck tumours: high prevalence in tonsillar localization. J Exp Clin 
Cancer Res. 2004;23:561–6.
 8. Daling JRMM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, 
Carter JJ, Porter PL, Galloway DA, McDougall JK. Human papillomavirus, 
smoking, and sexual practices in the etiology of anal cancer. Cancer. 
2004;101:270–80.
 9. Ragin C, Taioli E. Survival of squamous cell carcinoma of the head and 
neck in relation to human papillomavirus infection: review and meta‑
analysis. Int J Cancer. 2007;121:1813–20.
 10. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. 
Human papillomavirus type distribution in invasive cervical cancer 
and high‑grade cervical lesions: a meta‑analysis update. Int J Cancer. 
2007;121(3):621–32.
 11. Stanley MA. Genital human papillomavirus infections: current and pro‑
spective therapies. J Gen Virol. 2012;93(4):681–91.
 12. Castellsagué XDM, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, 
Peeling RW, Ashley R, Smith JS, Snijders PJ, et al. International Agency for 
Research on Cancer Multicenter Cervical Cancer Study Group Worldwide 
human papillomavirus etiology of cervical adenocarcinoma and its 
cofactors: implications for screening and prevention. J Natl Cancer Inst. 
2006;98:303–15.
 13. Bernard H‑U. The clinical importance of the nomenclature, evolution and 
taxonomy of human papillomaviruses. J Clin Virol. 2005;32:1–6.
 14. de Villiers E‑M, Fauquet C, Broker TR, Bernard H‑U, zur Hausen H. Classifica‑
tion of papillomaviruses. Virology. 2004;324(1):17–27.
 15. Schwartz SMDJ, Shera KA, Madeleine MM, McKnight B, Galloway DA, 
Porter PL, McDougall JK. Human papillomavirus and prognosis of invasive 
cervical cancer: a population‑based study. J Clin Oncol. 2001;19:1906–15.
 16. Graflund MSB, Sigurdardóttir S, Karlsson M. HPV‑DNA, vascular space 
invasion, and their impact on the clinical outcome in early‑stage cervical 
carcinomas. Int J Gynecol Cancer. 2004;14:896–902.
 17. Zuna R, Allen RA, Moore WE, Mattu R, Dunn ST. Comparison of human 
papillomavirus genotypes in high‑grade squamous intraepithelial lesions 
and invasive cervical carcinoma: evidence for differences in biologic 
potential of precursor lesions. Mod Pathol. 2004;17:1314–22.
 18. Begum S, Gillison ML, Ansari‑Lari MA, Shah K, Westra WH. Detection of 
human papillomavirus in cervical lymph nodes: a highly effective strategy 
for localizing site of tumor origin. Clin Cancer Res. 2003;9:6469–75.
 19. Umudum H, Rezanko T, Dag F, Dogruluk T. Human papillomavirus 
genome detection by in situ hybridization in fine‑needle aspirates of 
metastatic lesions from head and neck squamous cell carcinomas. Can‑
cer. 2005;105:171–7.
 20. Varnai A, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, 
Decker D. HPV in anal squamous cell carcinoma and anal intraepithelial 
neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and 
prognosis. Int J Colorectal Dis. 2006;2:135–42.
 21. Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez P‑Y, Al Moustafa 
A‑E. E6/E7 of HPV type 16 promotes cell invasion and metastasis of 
human breast cancer cells. Cell Cycle. 2007;6(16):2038–42.
 22. Niedobitek G, Meru N, Delecluse HJ. Epstein–Barr virus infection and 
human malignancies. Int J Exp Pathol. 2001;82(3):149–70.
 23. Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat Rev Cancer. 
2004;4(10):757–68.
 24. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles 
for Epstein–Barr virus (EBV) gene products in EBV‑associated proliferative 
disorders. Crit Rev Oncol Hematol. 2003;45(1):1–36.
 25. Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic 
states. Rev Med Virol. 2014;24(3):142–53.
 26. Cyprian FS, Al‑Farsi HF, Vranic S, Akhtar S, Al Moustafa A‑E. Epstein–Barr 
virus and human papillomaviruses interactions and their roles in the 
initiation of epithelial‑mesenchymal transition and cancer progression. 
Front Oncol. 2018;8:111.
 27. Banko AV, Lazarevic IB, Folic MM, Djukic VB, Cirkovic AM, Karalic DZ, 
et al. Characterization of the variability of Epstein–Barr virus genes in 
nasopharyngeal biopsies: potential predictors for carcinoma progression. 
PLoS ONE. 2016;11(4):e0153498.
 28. Shibata D, Weiss LM. Epstein–Barr virus‑associated gastric adenocarci‑
noma. Am J Pathol. 1992;140(4):769–74.
 29. Jácome AA, Lima EM, Kazzi AI, Chaves GF, Mendonça DC, Maciel MM, 
et al. Epstein–Barr virus‑positive gastric cancer: a distinct molecular 
subtype of the disease? Rev Soc Bras Med Trop. 2016;49(2):150–7.
 30. Hu H, Luo M‑L, Desmedt C, Nabavi S, Yadegarynia S, Hong A, et al. 
Epstein–Barr virus infection of mammary epithelial cells promotes malig‑
nant transformation. EBioMedicine. 2016;9:148–60.
 31. Al Moustafa A‑E, Al‑Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A. 
Co‑prevalence of Epstein–Barr virus and high‑risk human papillomavi‑
ruses in Syrian women with breast cancer. Human Vacc Immunotherap. 
2016;12(7):1936–9.
 32. Al‑Thawadi H, Ghabreau L, Aboulkassim T, Yasmeen A, Vranic S, Batist G, 
et al. Co‑incidence of Epstein‑Barr virus and high‑risk human papillomavi‑
ruses in cervical cancer of syrian women. Front Oncol. 2018;8:250.
 33. Landers RJ, O’Leary JJ, Crowley M, Healy I, Annis P, Burke L, et al. Epstein–
Barr virus in normal, pre‑malignant, and malignant lesions of the uterine 
cervix. J Clin Pathol. 1993;46(10):931–5.
Page 12 of 13Al‑Thawadi et al. Cancer Cell Int          (2020) 20:361 
 34. Wong KY, Collins RJ, Srivastava G, Pittaluga S, Cheung AN, Wong LC. 
Epstein–Barr virus in carcinoma of the cervix. Int J Gynecol Pathol. 
1993;12(3):224–7.
 35. Morales‑Sánchez A, Molina‑Muñoz T, Martínez‑López JL, Hernández‑San‑
cén P, Mantilla A, Leal YA, et al. No association between Epstein–Barr virus 
and mouse mammary tumor virus with breast cancer in Mexican women. 
Sci Rep. 2013;3:2970.
 36. Glaser SL, Hsu JL, Gulley ML. Epstein–Barr virus and breast cancer: state 
of the evidence for viral carcinogenesis. Cancer Epidemiol Biomark Prev. 
2004;13(5):688–97.
 37. Chu PG, Chang KL, Chen YY, Chen WG, Weiss LM. No significant associa‑
tion of Epstein–Barr virus infection with invasive breast carcinoma. Am J 
Pathol. 2001;159(2):571–8.
 38. Hilton DA, Brown LJ, Pringle JH, Nandha H. Absence of Epstein–Barr virus 
in carcinoma of the cervix. Cancer. 1993;72(6):1946–8.
 39. Payne S, Kernohan NM, Walker F. Absence of in situ hybridization evi‑
dence for latent‑ or lytic‑phase Epstein–Barr virus infection of preinvasive 
squamous lesions of the cervix. J Pathol. 1995;176(3):221–6.
 40. Shimakage M, Horii K, Tempaku A, Kakudo K, Shirasaka T, Sasagawa 
T. Association of Epstein‑–Barr virus with oral cancers. Hum Pathol. 
2002;33(6):608–14.
 41. Horiuchi K, Mishima K, Ichijima K, Sugimura M, Ishida T, Kirita T. Epstein–
Barr virus in the proliferative diseases of squamous epithelium in the 
oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 
1995;79(1):57–63.
 42. Al Moustafa A‑E, Chen D, Ghabreau L, Akil N. Association between human 
papillomavirus and Epstein–Barr virus infections in human oral carcino‑
genesis. Med Hypotheses. 2009;73(2):184–6.
 43. Busson P, McCoy R, Sadler R, Gilligan K, Tursz T, Raab‑Traub N. Consistent 
transcription of the Epstein–Barr virus LMP2 gene in nasopharyngeal 
carcinoma. J Virol. 1992;66(5):3257–62.
 44. Hitt MM, Allday MJ, Hara T, Karran L, Jones MD, Busson P, et al. EBV gene 
expression in an NPC‑related tumour. EMBO J. 1989;8(9):2639–51.
 45. Al Moustafa A, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, 
Batist G, Alpert L, Alaoui‑Jamali MA. E6/E7 proteins of HPV type 16 and 
ErbB‑2 cooperate to induce neoplastic transformation of primary normal 
oral epithelial cells. Oncogene. 2004;23:350–8.
 46. Al Moustafa A, Kassab A, Darnel A, Yasmeen A. High‑risk HPV/ErbB‑2 
interaction on E‑cadherin/catenin regulation in human carcinogenesis. 
Curr Pharm Des. 2008;14:2159–72.
 47. Al Moustafa A‑E. E5 and E6/E7 of high‑risk HPVs cooperate to 
enhance cancer progression through EMT initiation. Cell Adh Migr. 
2015;9(5):392–3.
 48. Al Moustafa A‑E, Cyprian FS, Al‑Antary N, Yasmeen A. High‑risk human 
papillomaviruses and Epstein–Barr virus presence and crosstalk in human 
oral carcinogenesis. In: Al Moustafa A‑E, editor. Development of oral can‑
cer: risk factors and prevention strategies. Cham: Springer International 
Publishing; 2017. p. 83–94.
 49. Darnel AD, Wang D, Ghabreau L, Yasmeen A, Sami S, Akil N, et al. Correla‑
tion between the presence of high‑risk human papillomaviruses and Id 
gene expression in Syrian women with cervical cancer. Clin Microbiol 
Infect. 2010;16(3):262–6.
 50. Aboulkassim T, Yasmeen A, Akil N, Batist G, Al Moustafa A‑E. Incidence of 
Epstein–Barr virus in Syrian women with breast cancer: a tissue microar‑
ray study. Hum Vacc Immunother. 2015;11(4):951–5.
 51. Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, Lawson JS. 
Epstein–Barr virus, human papillomavirus and mouse mammary tumour 
virus as multiple viruses in breast cancer. PloS ONE. 2012;7(11):e48788.
 52. Fuessel Haws AL, He Q, Rady PL, Zhang L, Grady J, Hughes TK, 
et al. Nested PCR with the PGMY09/11 and GP5 +/6 + primer sets 
improves detection of HPV DNA in cervical samples. J Virol Methods. 
2004;122(1):87–93.
 53. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa AE. 
High‑risk human papillomavirus infections in breast cancer in Syrian 
women and their association with Id‑1 expression: a tissue microarray 
study. Br J Cancer. 2008;99(3):404–7.
 54. Weiss P. Tumour‑inducing viruses. Br J Hosp Med. 2016;77(Sup10):565–8.
 55. Shi Y, Peng S‑L, Yang L‑F, Chen X, Tao Y‑G, Cao Y. Co‑infection of 
Epstein–Barr virus and human papillomavirus in human tumorigenesis. 
Chin J Cancer. 2016;35(1):16.
 56. Antonsson A, Wilson LF, Kendall BJ, Bain CJ, Whiteman DC, Neale RE. 
Cancers in Australia in 2010 attributable to infectious agents. Aust N Z 
J Public Health. 2015;39(5):446–51.
 57. Parkin DM. The global health burden of infection‑associated cancers in 
the year 2002. Int J Cancer. 2006;118(12):3030–44.
 58. Drop B, Strycharz‑Dudziak M, Kliszczewska E, Polz‑Dacewicz M. Coin‑
fection with Epstein–Barr Virus (EBV), human papilloma Virus (HPV) and 
polyoma BK virus (BKPyV) in laryngeal, oropharyngeal and oral cavity 
cancer. Int J Mol Sci. 2017;18(12):2752.
 59. Polz‑Gruszka D, Stec A, Dworzański J, Polz‑Dacewicz M. EBV, HSV, CMV 
and HPV in laryngeal and oropharyngeal carcinoma in polish patients. 
Anticancer Res. 2015;35(3):1657–61.
 60. Veitía D, Liuzzi J, Àvila M, De Guglielmo Z, Correnti M. Prevalence of 
HPV and EBV infection and their relationship with the p53 and PCNA 
expression in oral carcinoma patients. J Oral Res. 2017;4:86–91.
 61. Makielski KR, Lee D, Lorenz LD, Nawandar DM, Chiu Y‑F, Kenney SC, 
et al. Human papillomavirus promotes Epstein–Barr virus maintenance 
and lytic reactivation in immortalized oral keratinocytes. Virology. 
2016;495:52–62.
 62. Jalouli J, Jalouli MM, Sapkota D, Ibrahim SO, Larsson P‑A, Sand L. 
Human papilloma virus, herpes simplex virus and Epstein–Barr virus in 
oral squamous cell carcinoma from eight different countries. Antican‑
cer Res. 2012;32(2):571–80.
 63. Jalouli J, Ibrahim SO, Sapkota D, Jalouli MM, Vasstrand EN, Hirsch JM, 
et al. Presence of human papilloma virus, herpes simplex virus and 
Epstein–Barr virus DNA in oral biopsies from Sudanese patients with 
regard to toombak use. J Oral Pathol Med. 2010;39(8):599–604.
 64. Sand L, Wallstrom M, Hirsch JM. Smokeless tobacco, viruses and oral 
cancer. Oral Health Dent Manag. 2014;13(2):372–8.
 65. Kis A, Fehér E, Gáll T, Tar I, Boda R, Tóth ED, et al. Epstein–Barr virus 
prevalence in oral squamous cell cancer and in potentially malignant 
oral disorders in an eastern Hungarian population. Eur J Oral Sci. 
2009;117(5):536–40.
 66. Iljazović E, Mena M, Tous S, Alemany L, Omeragić F, Sadiković A, et al. 
Human papillomavirus genotype distribution in invasive cervical can‑
cer in Bosnia and Herzegovina. Cancer Epidemiol. 2014;38(5):504–10.
 67. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus 
types in head and neck squamous cell carcinomas worldwide: a sys‑
tematic review. Cancer Epidemiol Biomark Prev. 2005;14(2):467–75.
 68. Gabrielli Fregonesi PA, Teresa DB, Duarte RA, Neto CB, de Oliveira MRB, 
Soares CP. p16INK4A immunohistochemical overexpression in prema‑
lignant and malignant oral lesions infected with human papillomavi‑
rus. J Histochem Cytochem. 2003;51(10):1291–7.
 69. Shroyer KR, Greer RO. Detection of human papillomavirus DNA by 
in situ DNA hybridization and polymerase chain reaction in prema‑
lignant and malignant oral lesions. Oral Surg Oral Med Oral Pathol. 
1991;71(6):708–13.
 70. Agrawal GP, Joshi PS, Agrawal A. Role of HPV‑16 in pathogenesis of oral 
epithelial dysplasia and oral squamous cell carcinoma and correlation 
of p16INK4A expression in HPV‑16 positive cases: an immunohisto‑
chemical study. ISRN Pathol. 2013;2013:1–7.
 71. Tyan YS, Liu ST, Ong WR, Chen ML, Shu CH, Chang YS. Detection 
of Epstein–Barr virus and human papillomavirus in head and neck 
tumors. J Clin Microbiol. 1993;31(1):53–6.
 72. Tung YC, Lin KH, Chu PY, Hsu CC, Kuo WR. Detection of human papil‑
loma virus and Epstein–Barr virus DNA in nasopharyngeal carcinoma 
by polymerase chain reaction. Kaohsiung J Med Sci. 1999;15(5):256–62.
 73. Jiang R, Ekshyyan O, Moore‑Medlin T, Rong X, Nathan S, Gu X, et al. 
Association between human papilloma virus/Epstein–Barr virus coin‑
fection and oral carcinogenesis. J Oral Pathol Med. 2015;44(1):28–36.
 74. Shi Y, Peng S‑L, Yang L‑F, Chen X, Tao Y‑G, Cao Y. Co‑infection of 
Epstein–Barr virus and human papillomavirus in human tumorigenesis. 
Chin J Cancer. 2016;35:16.
 75. Guidry JT, Scott RS. The interaction between human papillomavirus 
and other viruses. Virus Res. 2017;231:139–47.
 76. Pattle SB, Farrell PJ. The role of Epstein‑Barr virus in cancer. Expert 
opinion on biological therapy. 2006;6(11):1193–205.
 77. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, et al. Strong correlation 
between c‑erbB‑2 overexpression and overall survival of patients with 
oral squamous cell carcinoma. Clin Cancer Res. 1997;3(1):3–9.
Page 13 of 13Al‑Thawadi et al. Cancer Cell Int          (2020) 20:361  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 78. Yasmeen A, Hosein AN, Yu Q, Al Moustafa A‑E. Critical role for D‑type cyc‑
lins in cellular transformation induced by E6/E7 of human papillomavirus 
type 16 and E6/E7/ErbB‑2 cooperation. Cancer Sci. 2007;98(7):973–7.
 79. Wei MX, de Turenne‑Tessier M, Decaussin G, Benet G, Ooka T. Establish‑
ment of a monkey kidney epithelial cell line with the BARF1 open reading 
frame from Epstein–Barr Virus. Oncogene. 1997;14(25):3073–81.
 80. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in 
immortalized lymphocytes transforms established rodent cells. Cell. 
1985;43(3):831–40.
 81. Wei MX, Ooka T. A transforming function of the BARF1 gene encoded by 
Epstein–Barr virus. EMBO J. 1989;8(10):2897–903.
 82. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck‑Wikland E. Human 
papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of 
relapse, and survival. Int J Cancer. 2000;89(3):300–4.
 83. Birdwell CE, Queen KJ, Kilgore PCSR, Rollyson P, Trutschl M, Cvek U, 
et al. Genome‑wide DNA methylation as an epigenetic consequence 
of Epstein–Barr virus infection of immortalized keratinocytes. J Virol. 
2014;88(19):11442–58.
 84. Birdwell CE, Prasai K, Dykes S, Jia Y, Munroe TGC, Bienkowska‑Haba M, 
et al. Epstein‑Barr virus stably confers an invasive phenotype to epi‑
thelial cells through reprogramming of the WNT pathway. Oncotarget. 
2018;9(12):10417–35.
 85. Guidry JT, Myers JE, Bienkowska‑Haba M, Songock WK, Ma X, Shi M, et al. 
Inhibition of Epstein–Barr virus replication in human papillomavirus‑
immortalized keratinocytes. J Virol. 2019;93(2):e01216–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
